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needed for monitoring incidence, which
is all some population-based registries do,
but such registries should still consider
adopting those parts of the proposed format
that are relevant to their concerns-and
as cancer control services become more
comprehensive, integrated and population-
based, the need is growing for population-
based registries to monitor outcome as well
as incidence. Some of the Handbook's
proposals for obtaining such information
have been criticized-notably its reckoning
of survival from presentation at hospital,
rather than from first treatment as has
been usual in England-but such changes
seem a small price to pay for international
comparability, and it is therefore to be
hoped that all cancer registries will do
what they can to incorporate the Handbook's
system in their own.
I. LECK
Directory of On-going Research in Can-
cer Epidemiology. (1976) Lyon: In-
ternational Agency for Research on Cancer,
and Heidelberg: Deutsches Krebsfors-
chungszentrum. 461 pp. No charge ex-
cept for postage and packing (US $5.00).
A year ago, it was reported in this and
other journals that the International Agency
for Research on Cancer, Lyon, and the
German Cancer Research Centre, Heidelberg,
were launching a Clearance-house for On-
going Research in Cancer Epidemiology, and
asking workers in this field to submit sum-
maries of their current projects for inclusion
in an annual Directory, with the aim of
acquainting those working in overlapping
fields with one another's studies and en-
couraging them to produce their results in
comparable form.
The first product of this venture is the
1976 Directory, containing summaries of
more than 600 projects, followed by sections
in which these projects are indexed by
tumour site and type, by " term " (most
of these " terms " being possible correlates
of incidence), by methodology, and by
country of origin. There is also a list of
population-based cancer registries.
The coverage provided is inevitably
uneven (some very distinguished workers'
reports are tantalisingly brief, and more
than half the projects listed are from the
United States and the United Kingdom,
as against less than 10% from the Soviet
Union and none from mainland China)
and some epidemiologists will regret the
apparent exclusion of health services research.
But the Directory still merits an enthusiastic
welcome, and it will probably soon come
to be regarded as indispensable. Future
issues might be somewhat improved by
including the pages on which each country's
entries start in the table of contents, and
by standardizing the indexing of cancer
sites so that, for example, studies of lower
respiratory tract cancer are not dispersed
between " bronchial", "lung " and " respi-
ratory " rubrics.
I. LECK
Breast Cancer: Trends in Research and
Treatment. Ed J. C. HEUSON, W. H.
MATTEIEM andM. ROZENCWEIG (1976). New
York: Raven Press. 335 pp. $28.50 net.
Allowing for the naturally slow tempo
of developments in clinical oncology, the
management of breast cancer is progressing
through a rapid and exciting phase. This
interest centres on the use of adjuvant
therapy in the early case. Much of this
is reflected in this EORTC monograph,
which is based on a conference held in
September 1975.
Information is presented on the thinking
behind adjuvant therapy and on some
of the early results. This form of therapy
can be hormonal or cytotoxic, and can use
agents singly or in combination. The trend
seems to be towards a combination of several
cytotoxic agents with a hormone preparation
(e.g. CMF plus Tamoxifen) but it is most
important that work of this sort is carried
out in a carefully controlled study, so that
reliable results can be obtained economically.
Due attention is given to short-term and
long-term toxicity. Some promising early
results are quoted, but it is still possible
that the end result will be prolongation of
recurrence-free interval (as has been demon-
strated years ago by the use of ovarian
ablation) rather than cure.
Before chemotherapy can be incorporated
into potentially curative regimes, there must
be preliminary assessment on patients withBOOK REVIEWS 515
late disease. Carter presents a mass of This book is recommended to clinicians
very useful data on single-agent and com- involved in the management of breast
bination chemotherapy in this group. cancer and, especially, to those who are
Attention is also given to hormone arranging clinical trials to assess adjuvant
studies, especially the current status of therapy.
receptor studies, and to some animal work
in virology and immunology. I. D. H. TODD